Cytokinetics Value Stock - Dividend - Research Selection
Cytokinetics
ISIN: US23282W6057 , WKN: A1W1KK
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company\'s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Cytokinetics (CYTK) Investor Presentation - Slideshow
2023-03-17
The following slide deck was published by Cytokinetics, Incorporated in conjunction with this event.
Mizuho Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
2023-03-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Aldeyra Therapeutics (ALDX)
2023-03-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Cantor Fitzgerald Sticks to Their Buy Rating for Cytokinetics (CYTK)
2023-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Cytokinetics to Participate in Upcoming Investor Conferences
2023-03-06
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time.Barclays Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will participate in a Fi
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
2023-03-06
Cytokinetics Incorporated (NASDAQ: CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%. High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit. Related: FDA Rejects Cytokinetics' Heart Failure Treatment Candidate. An improvement of ≥
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Seagen (SGEN) and BioVie (BIVI)
2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Qiagen (QGEN) and Dice Therapeutics (DICE)
2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Puma Biotechnology (PBYI) and Praxis Precision Medicines (PRAX)
2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Analysts` Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Incyte (INCY) and Seer (SEER)
2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.